enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. PXL065 - Wikipedia

    en.wikipedia.org/wiki/PXL065

    PXL065 (formerly known as DRX-065) has demonstrated preclinical efficacy for both NASH [1] and X-linked adrenoleukodystrophy (X-ALD). [2] In 2022, it successfully completed a 9 month Phase 2 trial in biopsy-proven NASH patients where it met the primary endpoint for reduction in liver fat without weight gain or edema.

  3. Madrigal- New Catalysts Boost Biotech - AOL

    www.aol.com/news/madrigal-catalysts-boost...

    We recently caught up with the management team at Madrigal Pharmaceuticals (MDGL) to provide an update as the all-important Phase III MAESTRO NASH trial, suggests John McCamant, editor of The ...

  4. Inventiva announces the publication in Nature Communications ...

    lite-qa.aol.com/pf/story/0022/20240513/...

    Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with ...

  5. Terns' Potential NASH Candidate Shows Potent Liver Target ...

    www.aol.com/news/terns-potential-nash-candidate...

    Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from a Phase 1 trial of TERN-501, a thyroid hormone receptor beta (THR-β) agonist, for NASH. TERN-501 was generally safe and ...

  6. US FDA declines to approve Intercept's fatty liver disease drug

    www.aol.com/news/us-fda-declines-approve...

    The rejection marks Intercept's second failed attempt at securing approval for the drug to treat patients with non-alcoholic steatohepatitis (NASH) - a liver disease that affects 5% of U.S. adults ...

  7. Tropifexor - Wikipedia

    en.wikipedia.org/wiki/Tropifexor

    In combination with cenicriviroc, a CCR2 and CCR5 receptor inhibitor, it is undergoing a phase II clinical trial for NASH and liver fibrosis. [ 2 ] Rats treated orally with tropifexor (0.03 to 1 mg/kg) showed an upregulation of the FXR target genes, BSEP and SHP , and a down-regulation of CYP8B1 .

  8. Cartesian Therapeutics Announces Positive Updated Results ...

    lite.aol.com/tech/story/0022/20241203/9312598.htm

    Updated Phase 2a Open-Label Trial Results Cartesian today also announced positive updated results from retreated participants enrolled in the Phase 2a open-label portion of the trial. Two participants were previously retreated, and experienced rapid improvement in clinical scores and maintained minimum symptom expression for up to one year ...

  9. Wonderland murders - Wikipedia

    en.wikipedia.org/wiki/Wonderland_murders

    In 1990, Nash was charged in California state court with having planned the murders, and Diles was charged as a participant. Thorson testified against them, but the trial ended with a hung jury vote of 11–1 for conviction. [14] A second trial, in 1991, ended in acquittal for both Nash and Diles. [15] Diles died from liver failure in 1997. [16]